

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A composition comprising an isolated and purified peptide ~~defined by~~ consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 14, ~~[[and]]~~ SEQ ID NO: 15, and a portion thereof, wherein said portion is ~~approximately~~ five amino acids in length.
2. (Previously Presented) The composition of Claim 1, wherein said peptide is suitable for the reduction of C5a binding to neutrophils.
3. (Withdrawn)¹ Antibodies produced from the peptide of claim 1.
4. (Withdrawn) A method, comprising:
 - a) providing;
 - i) neutrophils,
 - ii) a purified peptide having an amino acid sequence selected from the group of SEQ ID NO: 14 and SEQ ID NO: 15, and portions thereof; and
 - b) mixing said neutrophils with said peptide under conditions such that the ability of said neutrophils to bind full-length human C5a peptide is reduced.
5. (Withdrawn) The method of Claim 4, wherein said neutrophils are human neutrophils.
6. (Withdrawn) The method of Claim 4, wherein said neutrophils are murine neutrophils.
7. (Withdrawn) The method of Claim 4, wherein said neutrophils are rat neutrophils.

¹ The Examiner is reminded that 37 CFR 1.121 now requires non-elected claims identified as "Withdrawn" accompanied by their full text. See Restriction Requirement Mailed 09/10/02.

8. (Withdrawn) A method, comprising:
 - a) providing;
 - i) neutrophils,
 - ii) a purified peptide having an amino acid sequence selected from the group of SEQ ID NO: 14 and SEQ ID NO: 15, and portions thereof; and
 - b) treating said neutrophils with said peptide under such conditions that C5a activation of said neutrophils is inhibited.
9. (Withdrawn) The method of Claim 8, wherein said neutrophils are human neutrophils.
10. (Withdrawn) The method of Claim 8, wherein said neutrophils are murine neutrophils.
11. (Withdrawn) The method of Claim 8, wherein said neutrophils are rat neutrophils.
12. (Canceled)
13. (Previously Presented) The composition of Claim 1, further comprising adjuvant.
14. (Previously Presented) The composition of Claim 13, wherein said adjuvant is selected from the group consisting of agar beads, aluminum hydroxide, aluminum phosphate, incomplete Freund's, Quail A, Gerbu and bacterin.
15. (Canceled)
16. (Withdrawn) A composition comprising:
 - a) an isolated and purified variant C-terminal truncated C5a peptide that is between five and fifty amino acids in length, and;
 - b) adjuvant or buffered saline.

17. (Withdrawn) The compositions of Claim 16, wherein said variant C-terminal truncated C5a peptide is selected from the group consisting of SEQ ID NOS: 20-74.
18. (Withdrawn) The composition of Claim 16, wherein said adjuvant is selected from the group consisting of agar beads, aluminum hydroxide, aluminum phosphate, incomplete Freund's, Quail A, Gerbu and bacterin.
19. (Withdrawn) The composition of Claim 16, wherein said peptide is suitable for reduction of C5a binding to neutrophils.